PPAR-α regulates metabolic remodelling and participates in myocardial fibrosis in patients with atrial fibrillation of rheumatic heart disease

被引:1
|
作者
Hu, Xiaoying [1 ]
Jiang, Daisong
Zhang, Zheng
An, Zhenmei [2 ,3 ]
机构
[1] Zigong Fourth Peoples Hosp, Dept Lab Med, Zigong, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu, Peoples R China
关键词
peroxisome proliferator activated receptor-alpha; rheumatic heart disease; atrial fibrillation; metabolic remodelling; myocardial fibrosis; correlation study; ACTIVATION;
D O I
10.5114/aoms/181134
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: This study will explore the correlation of peroxisome proliferator activated receptor-alpha (PPAR-alpha) regulation of metabolic remodelling in the myocardial fibrosis of atrial fibrillation (AF) in rheumatic heart disease. Material and methods: The left atrial appendage tissues were evaluated by Masson staining for fibrosis degree, and Western Blot was used to detect the expression of proteins related to glucose metabolism disorder, lipid metabolism abnormality, and mitochondrial dysfunction. The myocardial fibroblasts were established by stimulation with ANG II, and the PPAR-alpha agonist GW7647 was administered. The changes of phenotype transformation of myocardial fibroblasts were detected by cellular immunofluorescence, the secretion level of supernatant collagen was detected by ELISA. Finally, the correlation between PPAR-alpha protein expression and myocardial fibrosis was analysed and a conclusion was drawn. Results: Masson staining showed that the degree of myocardial fibrosis in patients with AF was significantly increased; WB analysis showed that there were statistically significant differences in protein expression related to glucose metabolism disorder, lipid metabolism abnormality, and mitochondrial dysfunction. There was a correlation between PPAR-alpha protein expression and myocardial fibrosis (r = -0.5322, p < 0.0001). After stimulation with PPAR-alpha agonist GW7647, the phenotypic differentiation of myocardial fibro-blasts into myofibroblasts was inhibited. The protein expression related to mitochondrial dysfunction was statistically different. Conclusions: This study found that there is a negative correlation between the expression of PPAR-alpha protein and myocardial fibrosis in rheumatic heart disease AF, which plays a protective role. PPAR-alpha may participate in the pathogenesis of myocardial fibrosis in rheumatic heart disease AF by regulating glucose metabolism, lipid metabolism, and mitochondrial function.
引用
收藏
页码:1461 / 1471
页数:11
相关论文
共 50 条
  • [1] Relationship of CTGF, HGF and atrial fibrosis in patients with atrial fibrillation during rheumatic heart disease
    Yi, Xin
    Zhou, Yanli
    Ma, Lele
    Li, Mingjiang
    CARDIOLOGY, 2013, 126 : 165 - 166
  • [2] Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-/sirtuin 1/PGC-1 pathway
    Liu, Guang-zhong
    Hou, Ting-ting
    Yuan, Yue
    Hang, Peng-Zhou
    Zhao, Jing-jing
    Sun, Li
    Zhao, Guan-qi
    Zhao, Jing
    Dong, Jing-mei
    Wang, Xiao-bing
    Shi, Hang
    Liu, Yong-wu
    Zhou, Jing-hua
    Dong, Zeng-xiang
    Liu, Yang
    Zhan, Cheng-chuang
    Li, Yue
    Li, Wei-min
    BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (06) : 1095 - 1109
  • [3] Snail1 is positively correlated with atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease
    Guo, Furong
    Yi, Xin
    Li, Mingjiang
    Fu, Jinrong
    Li, Sha
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (05) : 4231 - 4237
  • [4] Atrial Fibrillation in Rheumatic Heart Disease
    Bansal, Ankit
    Sarkar, Prattay Guha
    Chaturvedi, Vivek
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2020, 22 (11)
  • [5] Atrial Fibrillation in Rheumatic Heart Disease
    Ankit Bansal
    Prattay Guha Sarkar
    Vivek Chaturvedi
    Current Treatment Options in Cardiovascular Medicine, 2020, 22
  • [6] Fibroblast growth factor-21 is positively associated with atrial fibrosis in atrial fibrillation patients with rheumatic heart disease
    Wang, Rui
    Yi, Xin
    Li, Xiaoyan
    Jiang, Xuejun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 14901 - 14908
  • [7] A STUDY OF ATRIAL FIBRILLATION IN RHEUMATIC HEART DISEASE
    Boddu, Jyotirmayi
    Reddy, V. C. Srinivas
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2018, 7 (08): : 1020 - 1023
  • [8] Anticoagulation in Atrial Fibrillation and Rheumatic Heart Disease
    Lip, Gregory Y. H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (11): : 1036 - 1038
  • [9] Management of atrial fibrillation in rheumatic heart disease
    Shenthar, Jayaprakash
    HEART RHYTHM O2, 2022, 3 (06): : 752 - 759
  • [10] Results of Surgical Ablation for Atrial Fibrillation in Patients with Rheumatic Heart Disease
    Albacker, Turki B.
    Alaamro, Sultan
    Alhothali, Abdulaziz M.
    Arafat, Amr A.
    Algarni, Khaled D.
    Eldemerdash, Ahmed
    Bakir, Bakir M.
    JOURNAL OF THE SAUDI HEART ASSOCIATION, 2022, 34 (04) : 241 - 248